ECM
QNCX icon

ExodusPoint Capital Management’s Quince Therapeutics QNCX Stock Holding History

ExodusPoint Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-113
Closed -$633K – 2510
2020
Q4 		$633K Buy
+113
New +$1M 0.01% 1104

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ExodusPoint Capital Management's QNCX Position: Q1 2022 in Review

ExodusPoint Capital Management sold out of Quince Therapeutics (QNCX) in Q1 2022, closing a stake of 153 shares — an estimated $385K sold.

ExodusPoint Capital Management first reported a position in QNCX in Q4 2020 and held it in 4 quarters. The position peaked at $385K in Q4 2021. 85 funds tracked by Wall St. Rank hold QNCX as of Q1 2022.

  • ExodusPoint Capital Management reported no remaining Quince Therapeutics position as of Q1 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 153 Quince Therapeutics shares in Q1 2022, an estimated $385K.
  • ExodusPoint Capital Management first reported a position in Quince Therapeutics in Q4 2020 and held it in 4 quarters.
  • ExodusPoint Capital Management's Quince Therapeutics position peaked at $385K in Q4 2021.
  • 85 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.